PCVX FY 2023 Earnings — Vaxcyte, Inc. Revenue & Financial Results | Market Cap Arena

PCVXVaxcyte, Inc.

$9B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$468M

Net Income

-$402M

EPS (Diluted)

$-4.14

Cash Flow

Operating Cash Flow

-$297M

Free Cash Flow

-$365M

Stock-Based Comp.

$49M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$167M

Stockholders' Equity

$1.2B

Cash & Equivalents

$397M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$468M	-$232M	-101.5%
Net Income	-$402M	-$223M	-80.0%